Tuesday, April 20, 2021
Home Life Style Health & Fitness National Institutes Of Health Examines Allergic Reactions To COVID-19 Vaccines

National Institutes Of Health Examines Allergic Reactions To COVID-19 Vaccines

The U.S. National Institutes of Health (NIH) announced Wednesday a clinical trial was underway to determine the risk of allergic reactions to the COVID-19 vaccines manufactured by Moderna and Pfizer.

A press release from the National Institutes of Health says the trial will determine whether people are highly allergic to the vaccine or have a disorder that puts them at an increased risk for an immediate, systemic allergic reaction to the vaccine.

Follow NewsGram on Instagram to keep yourself updated.

While the vaccines are considered safe, several rare allergic reaction incidents — including serious episodes, known as anaphylaxis — have been reported in the U.S. after Pfizer-BioNTech and Moderna shots were given.

National Institutes
The advantages of the COVID-19 vaccination greatly outweigh the disadvantages. Pixabay

The trial will also examine the biological mechanism behind allergic reactions in the body and whether a certain genetic pattern or other factors can be used to predict high-risk recipients.

“The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving these two vaccines. However, for most people, the benefits of COVID-19 vaccination far outweigh the risks,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, said in the statement.

NIH says a mast cell disorder is a disease caused by a type of white blood cell called a mast cell that is abnormal, overly active, or both, predisposing a person to life-threatening reactions.

The Phase 2 trial, called Systemic Allergic Reactions to SARS-CoV-2 Vaccination, is sponsored and funded by NIAID.

ALSO READ: Post-COVID World Requires Equitable Healthcare access: World Health Organization

The vaccines used in the trial are provided by the program led by the U.S. Department of Health and Human Services and the U.S. Department of Defense that develops COVID-19 vaccines and therapeutics.

The study will include 3,400 adults ages 18 to 69 at up to 35 academic allergy research centers nationwide. (VOA/KB)

STAY CONNECTED

19,517FansLike
362FollowersFollow
1,773FollowersFollow

Most Popular

More Urban Indians Suffer Payment App Frauds, Card Frauds: Report

More urban Indians are facing payment app frauds (24 percent), identity thefts (20 percent), and payment card frauds (18 percent) than ever before during...

Rapprochement Between Russia And The US?

The recent announcement by the White House sources that US President Joe Biden has proposed that he and his Russian counterpart Vladimir Putin hold...

Recognize And Seize Your Serendipitous Moments: Neil J. Farber

Archimedes' discovery of the relationship of weight, volume, and density of materials, Alexander Fleming's discovery of penicillin, Samuel Morse devising the Morse code, Alexander...

Sweat Sensor Alerts Doctors And Patients To Impending Cytokine Storm In Real Time

Scientists have developed a sweat sensor that acts as an early warning system for a looming cytokine storm -- a surge of pro-inflammatory immune...

Gender-Affirming Hormone Therapy Associated With High BP Risk

Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research. Although doctors have prescribed...

Nanking Massacre: The Holocaust

By- Khushi Bisht The Nanking Massacre, also known as the Rape of Nanking, was one of the worst massacres committed during the Sino-Japanese war that...

‘Child Of Two Worlds’ Featuring The Protagonists And Immortal Lovers

Turkey-based author Ann D'Silva has launched her new book "Child of Two Worlds", which is second in the fictional 'Sand and Sea' series, which...

Now Transfer Posts And Notes To Google Docs And WordPress Directly

Facebook on Monday introducing two new data portability types that will help users directly transfer their posts and notes to Google Documents, Blogger, and...

Recent Comments